Anebulo Pharmaceuticals, Inc.
ANEB
$1.14
$0.065.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 26.92% | 31.72% | 30.09% | 19.14% | 1.37% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 650.94% | -- | -- | -- | -- |
| Total Other Non-Cash Items | 34.50% | -5.50% | -14.22% | -9.32% | 11.08% |
| Change in Net Operating Assets | -16,670.83% | -152.21% | -168.64% | -123.75% | -99.86% |
| Cash from Operations | 30.63% | 32.02% | 16.44% | -0.61% | -18.22% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 80.32% | 80.32% | 47.53% | 47.53% |
| Cash from Financing | 11,585.45% | 80.32% | -100.98% | -102.02% | -102.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 186.03% | 33.45% | -146.99% | -278.43% | -487.22% |